Nipocalimab

Also known as M281.

Latest news on nipocalimab

7 November 2026
Johnson & Johnson: DAHLIAS Phase 2 finds mouth dryness is top-priority symptom for Sjögren’s patients

Exit interviews found 96% reported mouth dryness and linked symptom relief to better daily functioning; Phase 2 saliva gains with nipocalimab helped shape the Phase 3 DAFFODIL design.

3 June 2026
Johnson & Johnson: nipocalimab lowers SLE disease activity in Phase 2 JASMINE study

Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.

27 April 2026
Johnson & Johnson’s IMAAVY granted FDA Priority Review for wAIHA

FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.